Consensus Biogen Inc.

Stocks

BIIB

US09062X1037

Pharmaceuticals

Market Closed - Nasdaq 23:00:00 25/09/2026 +03			5-day change	1st Jan Change
227.60 ^USD	+0.55%		+5.61%	+29.33%

09-23	AI-based drug developer Basecamp valued at $800 million after $140 million funding round	RE
09-17	Biogen Publishes Phase 3 Pediatric EMPAVELI Data Showing Reduction in Proteinuria and Stabilized Kidney Function in Adolescents with C3g or Primary IC-MPGN	CI

Evolution of the Average Target: Biogen Inc.

Evolution of the Target Price: Biogen Inc.

Changes in Analyst Recommendations: Biogen Inc.

3.QMxaWFmDtyYKXgrRNtLSm08qeBTYecvMVV1xgylvFLQ.NZ8uAQjs2XY_DUvifJXlq38ZM2GsLv30ES4AwWxYVYwkgjNtO-3ua0EqXw~29a1217ee4f88cb9057f8f7f767d6fd1

Analysts' recommendations: Biogen Inc.

09-03	Piper Sander Adjusts Biogen Price Target to $245 From $225, Maintains Overweight Rating	MT
08-25	RBC Capital Adjusts Price Target on Biogen to $260 From $240, Keeps Outperform Rating	MT
08-25	RBC Adjusts Price Target on Biogen to $260 From $240, Maintains Outperform Rating	MT
08-25	RBC Capital Adjusts Price Target on Biogen to $260 From $240	MT
08-13	Wolfe Upgrades Biogen to Outperform From Peer Perform, Price Target is $300	MT
08-10	HSBC Adjusts Price Target on Biogen to $165 From $157, Keeps Reduce Rating	MT
08-03	Mizuho Adjusts Price Target on Biogen to $241 From $221	MT
07-30	BMO Capital Adjusts Price Target on Biogen to $208 From $196, Maintains Market Perform Rating	MT
07-30	TD Cowen Adjusts Price Target on Biogen to $225 From $215, Maintains Buy Rating	MT
07-30	Canaccord Genuity Adjusts Price Target on Biogen to $248 From $245, Maintains Buy Rating	MT
07-30	Goldman Sachs Adjusts Price Target on Biogen to $290 From $271, Maintains Buy Rating	MT
07-30	BMO Raises Price Target on Biogen to $208 From $196, Keeps Market Perform Rating	MT
07-30	UBS Adjusts Price Target on Biogen to $240 From $225, Maintains Buy Rating	MT
07-30	RBC Trims Price Target on Biogen to $240 From $242, Keeps Outperform Rating	MT
07-29	JPMorgan Lifts Biogen Price Target to $210 From $185	MT
07-29	Wedbush Adjusts Biogen Price Target to $215 From $201, Maintains Neutral Rating	MT
07-29	Stifel Nicolaus Adjusts Biogen Price Target to $242 From $214	MT
07-28	Barclays Adjusts Biogen Price Target to $200 From $185, Maintains Equalweight Rating	MT
07-24	Rothschild & Co Redburn Adjusts Price Target on Biogen to $210 From $190, Maintains Neutral Rating	MT
07-21	BofA Securities Adjusts Biogen Price Target to $215 From $217	MT
07-21	Guggenheim Adjusts Price Target on Biogen to $280 From $260, Maintains Buy Rating	MT
07-20	Goldman Sachs Adjusts Price Target on Biogen to $271 From $250, Maintains Buy Rating	MT
07-14	Cantor Fitzgerald Adjusts Biogen Price Target to $237 From $206	MT
07-13	Wedbush Raises Price Target on Biogen to $201 From $196, Keeps Neutral Rating	MT
07-13	Analyst recommendations: Biogen, Deckers Outdoor, Fortinet, Marathon Petroleum, UnitedHealth…

More recommendations

Biopharmaceuticals

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	BIOGEN INC.					+5.22%
	REGENERON PHARMACEUTICALS, INC.					+6.89%
	MODERNA, INC.					-38.63%
	CSL LIMITED					+0.52%
	SAMSUNG BIOLOGICS CO.,LTD.					+44.41%
	UCB					+34.5%
	INCYTE CORPORATION					+2.65%
	INNOVENT BIOLOGICS, INC.					+29.36%
	SWEDISH ORPHAN BIOVITRUM AB					+14.89%
	BRIDGEBIO PHARMA, INC.					+64.6%
	Average					+16.44%
	Weighted average by Cap.					+7.45%